Sumitomo Dainippon Pharma Annual Report 2017

Eleven-Year Summary of Selected Financial DataSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31¥379,513152,22640.1%110,030238,53168,16018.0%30,9528.2%25,05016,796(12,066)¥333,00069,794589,868157,204108,681323,983¥ 8,66344,62877,971¥ 42.27815.4418.005.0%2.8%54.9%42.6%¥296,26253,01517.9%112,263148,37451,37117.3%35,62512.0%31,42320,95827,148¥287,55574,084626,743265,00018,260343,483¥ 6,47118,65056,448¥ 52.75864.5118.006.3%4.1%54.8%34.1%¥264,03722,0518.4%103,741129,13052,81920.0%31,16611.8%32,16819,988—¥263,54069,105391,29553,35013,449324,496¥ 10,56911,45541,970¥ 50.30816.4918.006.2%5.1%82.9%35.8%¥263,99324,5219.3%99,385124,79447,26617.9%39,81415.1%41,45725,592—¥251,06370,280399,79167,91513,598318,278¥ 15,49111,87048,802¥ 64.39800.6318.008.2%6.5%79.6%28.0%¥261,21322,0328.4%99,346116,31240,87015.6%45,55517.4%38,41522,605—¥234,31365,241382,53556,03920,484306,012¥ 9,54312,00854,875¥ 56.86767.5214.007.6%5.8%79.8%24.6%20112010200920082007RESULTS OF OPERATIONS: Net sales Overseas sales revenue Ratio of overseas sales revenue Cost of sales Selling, general and administrative expenses (Research and development costs) (Ratio of net sales) Operating income Operating margin Income before income taxes Net income attributable to owners of the parent Comprehensive income (loss)FINANCIAL POSITION: Current assets Net property, plant and equipment Total assets Current liabilities Long-term liabilities Net assetsOTHER STATISTICS: Capital expenditures Depreciation and amortization EBITDAPER SHARE OF COMMON STOCK: Basic net income Net assets Cash dividends applicable to the yearFINANCIAL INDICATORS: ROE ROA Equity ratio Dividend payout ratioNotes 1. The U.S. dollar amounts in this report represent translations of Japanese yen solely for the reader’s convenience at the rate of ¥112 to US$1.00, the approximate rate of exchange at March 31, 2017.2. On June 19,2014, Dainippon Sumitomo Pharma Co., Ltd changed its name to Sumitomo Dainippon Pharma Co., Ltd. in preparation for global development. 3. Sumitomo Dainippon Pharma Co., Ltd. acquired Sepracor Inc. (now Sunovion Pharmaceutical Inc.) in October 2009. Consolidated results for the scal year ended March 31, 2010 include the results of this company for 2.5 months (October 15 - December 31, 2009).Sumitomo Dainippon Pharma Co., Ltd. Annual Report 201761Financial Section

元のページ  ../index.html#62